AbbVie separates from Abbott
January 7, 2013
THIS month sees the launch of a
new biopharmaceutical company,
AbbVie, following its separation
from Abbott.
Employing 21,000 people across
40 countries, including 200
Australians, the company’s
portfolio includes both growth
brands and durable performers,
including Humira, AndroGel,
Lupron, Synagis, Creon, Synthroid,
Kaletra, Norvir and Zemplar.
According to AbbVie, the company’s
long term growth will be fueled by
a compelling pipeline of more than
20 mid to late stage clinical programs,
as well as new discoveries to
address diseases including Hepatitis
C, rheumatoid arthritis, psoriasis,
multiple sclerosis, Alzheimer’s
disease, Parkinson’s disease,
spondyloarthropathies, multiple
myeloma and endometriosis.
“The company’s mission is to use
its expertise, dedicated people and
unique approach to innovation to
develop and market advanced
therapies that address some of the
world’s most complex and serious
diseases,” an AbbVie statement said.
Meanwhile, before its launch as
an independent entity, AbbVie
tripled the number of new
molecular entities in its
pipeline over the last several years.
The above article was sent to subscribers in Pharmacy Daily's issue from 07 Jan 13To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 07 Jan 13
